StockNews.com Initiates Coverage on Biocept (NASDAQ:BIOC)

Equities researchers at StockNews.com initiated coverage on shares of Biocept (NASDAQ:BIOC – Get Rating) in a research note issued to investors on Saturday. The brokerage set a “hold” rating on the medical research company’s stock.

BIOC has been the topic of several other reports. Maxim Group downgraded Biocept from a “buy” rating to a “hold” rating in a research report on Friday, April 14th. Brookline Capital Management cut Biocept from a “buy” rating to a “hold” rating in a research report on Friday, January 6th.

Biocept Stock Down 0.7 %

BIOC opened at $0.27 on Friday. The business has a 50 day moving average price of $0.35 and a 200 day moving average price of $0.54. Biocept has a twelve month low of $0.24 and a twelve month high of $1.75. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.83 and a current ratio of 2.97. The firm has a market cap of $4.74 million, a P/E ratio of -0.14 and a beta of 0.92.

Institutional Trading of Biocept

A hedge fund recently raised its stake in Biocept stock. Renaissance Technologies LLC grew its holdings in Biocept, Inc. (NASDAQ:BIOC – Get Rating) by 27.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 116,400 shares of the medical research company’s stock after purchasing an additional 24,800 shares during the quarter. Renaissance Technologies LLC owned about 0.69% of Biocept worth $270,000 as of its most recent filing with the SEC. Institutional investors own 10.04% of the company’s stock.

About Biocept

(Get Rating)

Biocept, Inc is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.